GLP-1 Drugs and Alcohol: Do They Cut Cravings? Evidence Reviewed (2026)

Last updated: June 2026

Medical disclaimer: This article is for informational purposes only and is not medical advice. GLP-1 drugs are not FDA-approved to treat alcohol use disorder. Do not start, stop, or change any treatment based on what you read here. Consult your doctor.

People started noticing it on their own. Patients on Ozempic or Wegovy for weight loss kept saying the same thing: they did not want to drink anymore. That flood of self-reports pushed researchers to test it for real.

This review pulls the actual numbers from the human trials and the large real-world studies. Every figure is cited to a primary source. The short version is that the science is early but moving fast, and the signal is real.

Do GLP-1 drugs reduce alcohol cravings?

Yes, early human trials show GLP-1 drugs can lower alcohol cravings and cut heavy drinking, but the effect is modest and not yet proven in large trials. No GLP-1 drug is approved to treat alcohol use disorder (AUD).

The clearest evidence comes from a 2025 randomized trial of semaglutide. People on the drug reported less weekly craving and drank less in a controlled lab setting (JAMA Psychiatry, 2025).

A larger 2026 trial backed this up. Adults with both AUD and obesity who took semaglutide had fewer heavy drinking days and lower cravings than those on placebo (Lancet, 2026).

Here is the honest framing. These are small-to-medium studies, and the effect sizes are moderate. They are strong enough to justify big trials, not strong enough to call it a treatment.

It helps to separate two questions. One is whether the drugs lower craving, which the trials suggest they do. The other is whether that translates into people drinking less over months, which is harder to prove and where the data thins out.

What does the clinical trial evidence show?

Two randomized semaglutide trials and one exenatide trial form the human evidence base, and all three point the same direction: less drinking, with the biggest effect in people who also have obesity.

The landmark study is the 2025 phase 2 trial led by Hendershot and colleagues at UNC. They randomized 48 adults with AUD to low-dose semaglutide (up to 1.0 mg) or placebo for 9 weeks (JAMA Psychiatry, 2025).

The results were notable for such a small study. Semaglutide reduced grams of alcohol consumed and peak breath alcohol in a lab session, and it cut drinks per drinking day and weekly craving versus placebo (JAMA Psychiatry, 2025).

The 2026 Lancet trial went bigger and longer. It enrolled 108 people with AUD plus obesity, gave them the full 2.4 mg weight-loss dose for 26 weeks on top of cognitive behavioral therapy, and measured heavy drinking days (Lancet, 2026).

Adding semaglutide to therapy cut heavy drinking days, drinks per drinking day, and self-reported cravings more than therapy alone (NIH, 2026).

The exenatide trial from Denmark is the cautionary tale. Klausen and colleagues randomized 127 people with AUD to weekly exenatide or placebo for 26 weeks. On the main outcome, heavy drinking days, the drug did no better than placebo (Klausen et al., JCI Insight, 2022).

But the exenatide trial held a clue. In the subgroup of patients with obesity, exenatide did cut heavy drinking and total intake, and brain scans showed reduced alcohol cue reactivity in reward regions (Klausen et al., JCI Insight, 2022).

That obesity pattern shows up again and again. It is the thread that ties the trials together. See the full <a href="#trial-table">trial table</a> below.

<a id="trial-table"></a>

Trial and study evidence: GLP-1 drugs and alcohol outcomes

Study (author, year)	Drug	Design / n	Alcohol outcome
Hendershot et al., 2025 (JAMA Psychiatry)	Semaglutide (low dose)	RCT, n=48, 9 wk	Lower craving, fewer drinks per drinking day, less lab alcohol intake
Lancet trial, 2026	Semaglutide 2.4 mg	RCT, n=108, 26 wk	Fewer heavy drinking days, lower craving (AUD + obesity)
Klausen et al., 2022 (JCI Insight)	Exenatide 2 mg	RCT, n=127, 26 wk	No overall effect; benefit only in obese subgroup
Wang/Volkow et al., 2024 (Nature Communications)	Semaglutide	EHR cohort, n=83,825	50-56% lower incidence and recurrence of AUD
Subhani et al., 2024 (eClinicalMedicine)	GLP-1 RAs (class)	Systematic review, 6 studies, n=88,190	May reduce alcohol consumption; evidence still limited
Quddos et al., 2023 (Scientific Reports)	Semaglutide / tirzepatide	Observational, obesity	Lower self-reported intake and binge drinking

Why might GLP-1 drugs affect drinking?

GLP-1 drugs appear to dial down the brain's reward response to alcohol, working on the same dopamine pathways that drive craving and addiction.

The brain has GLP-1 receptors in its reward regions, not just in the gut. These include the ventral tegmental area and the nucleus accumbens, the core of the mesolimbic dopamine system (Klausen et al., JCI Insight, 2022).

Alcohol gives a dopamine hit in this circuit, and that hit is part of what makes it rewarding. GLP-1 signaling seems to blunt that surge.

In the exenatide trial, brain scans showed less activation in reward areas when patients saw alcohol cues. Dopamine transporter availability also dropped (Klausen et al., JCI Insight, 2022).

Animal work tells the same story. Rodents given semaglutide or tirzepatide drink less alcohol and show weaker relapse-like behavior, alongside dampened dopamine reward signaling (eBioMedicine, 2025).

So the mechanism is plausible and consistent across species. It is the same reward-pathway logic behind testing these drugs for smoking and opioids, which we cover in our GLP-1 for opioid use disorder research review.

What does the real-world and observational data show?

Large real-world studies of people already taking these drugs for weight or diabetes show consistently lower rates of alcohol problems. These studies cannot prove cause and effect, but the size of the signal is hard to ignore.

The biggest is a 2024 electronic health record study. Among 83,825 patients with obesity, those on semaglutide had a 50-56% lower risk of both developing and relapsing into AUD over 12 months versus other weight drugs (Wang/Volkow et al., Nature Communications, 2024).

The pattern held in nearly 600,000 patients with type 2 diabetes, and across age, sex, and race subgroups (Wang/Volkow et al., Nature Communications, 2024).

A 2024 systematic review pulled the field together. Across six studies and 88,190 people, GLP-1 drugs were linked to less drinking, but the authors stressed how thin the high-quality data still was (Subhani et al., eClinicalMedicine, 2024).

Self-reports add color, not proof. In one observational study of people with obesity, both semaglutide and tirzepatide users reported lower intake and less binge drinking (Quddos et al., Scientific Reports, 2023).

Treat all of this as a strong hypothesis generator. People who choose these drugs differ from those who do not, and that bias can inflate an effect.

Real-world studies also cannot rule out that weight loss itself changes drinking habits. Someone losing 15% of their body weight may overhaul their whole routine, alcohol included. Only a randomized trial can isolate the drug from the lifestyle.

How does the effect differ by drug and dose?

The clearest human data is for semaglutide, the exenatide signal is limited to people with obesity, and tirzepatide is still early, but a dose and obesity pattern runs through all of it.

Semaglutide has the most direct evidence. Two randomized trials show lower craving and drinking, and the effect looked larger at the higher dose in the 2025 study (JAMA Psychiatry, 2025).

Exenatide is the weakest of the three. It missed its main target overall and only worked in patients with obesity (Klausen et al., JCI Insight, 2022).

Tirzepatide, the dual GIP/GLP-1 drug, has no published randomized AUD trial yet. The evidence is observational plus strong rodent data, and dedicated human trials are now enrolling (eBioMedicine, 2025).

Here is the through-line. Higher doses and the presence of obesity both seem to predict a bigger drop in drinking.

That obesity link matters for interpretation. It may mean the drugs work best in people who are also losing weight, or that the metabolic and reward effects overlap. The 2026 Lancet trial was built around exactly this AUD-plus-obesity group (Lancet, 2026).

This mirrors how other off-label GLP-1 uses are unfolding, where subgroup signals come first. Our semaglutide for smoking cessation early evidence review tracks a similar arc.

Should anyone use a GLP-1 for alcohol cravings right now?

No GLP-1 drug is FDA-approved for alcohol use disorder, so using one for cravings is off-label and not supported by approval-grade evidence. That does not mean it is worthless. It means the proof is not there yet.

The approved AUD treatments, naltrexone, acamprosate, and disulfiram, have decades of trial data behind them. GLP-1 drugs have a handful of small studies (NIAAA, 2026).

If you are on a GLP-1 for weight or diabetes and notice less interest in alcohol, that fits the research. Tell your doctor, but do not change your dose on your own.

If you have AUD and want help, start with treatments that are proven and approved. A GLP-1 might become an option later, but the trials that would justify it are still running.

The drugs also carry real side effects, mostly gastrointestinal, and were studied in specific populations. None of the AUD trials looked at pregnancy, teens, or long-term safety for this use (Lancet, 2026).

For the broader picture of where these drugs are proven versus promising, see our GLP-1 medications benefits roundup.

The bottom line

The story here is genuinely exciting and genuinely unfinished. Patients noticed it first, the lab work backs it up, and a real mechanism explains why.

Two randomized semaglutide trials now show lower cravings and less heavy drinking, with the strongest effect in people who also have obesity (JAMA Psychiatry, 2025; Lancet, 2026).

But none of this is approval-grade. The trials are small, the exenatide data was mixed, and large studies are still reading out (Subhani et al., eClinicalMedicine, 2024).

Promising, not proven. That is the honest line in 2026.

Related Reading

• GLP-1 for opioid use disorder research review
• Semaglutide for smoking cessation: early evidence
• GLP-1 medications benefits: what the latest research shows

Frequently asked questions

Does Ozempic stop alcohol cravings?

Some people on Ozempic (semaglutide) report fewer alcohol cravings, and early randomized trials support that effect. But semaglutide is not FDA-approved for alcohol use disorder, and the trials so far are small. The evidence is promising, not conclusive (JAMA Psychiatry, 2025).

Is any GLP-1 drug FDA-approved to treat alcohol use disorder?

No. As of 2026, no GLP-1 receptor agonist is approved for alcohol use disorder. Approved treatments remain naltrexone, acamprosate, and disulfiram (NIAAA, 2026).

Which GLP-1 drug has the best evidence for drinking?

Semaglutide. It is the only one with two randomized human trials showing lower craving and drinking. Exenatide missed its main goal except in people with obesity, and tirzepatide has no published randomized AUD trial yet (Lancet, 2026).

Why would a diabetes drug affect drinking at all?

GLP-1 receptors sit in the brain's reward system, not just the gut. By dampening the dopamine surge alcohol triggers, these drugs appear to lower its pull, the same circuit involved in addiction (Klausen et al., JCI Insight, 2022).

Should I ask my doctor about a GLP-1 for my drinking?

You can raise it, but know it would be off-label and unproven for that use. If you have alcohol use disorder, start with approved treatments. If you are already on a GLP-1 and drink less, tell your doctor but do not change your dose yourself.

-- The GLP-1 Daily Team